Home Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.12, p.861–865, 2021

Journal info


 


Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

 

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.122, No.12, p.861–865, 2021

Title: COVID-19 symptom duration predicts immunoglobulin G seropositivity
Author: L. Stepanek, M. Nakladalova, L. Stepanek, M. Janosikova, A. Borikova, H. Vildova
Abstract: OBJECTIVES: The study focused on the relationship between routine clinical characteristics and anti-SARS-CoV-2 specific antibodies in a pilot sample of healthcare workers (HCWs) having suffered COVID-19. The aim was to investigate the existence of readily available predictors of antibodies against COVID-19.
METHODS: As part of the recognition of COVID-19 as an occupational disease in 152 HCWs with the mean age of 43.2 years, personal, anthropometric and anamnestic data related to the disease as well as anti-spike immunoglobulin (Ig) levels were obtained. Through descriptive statistics, correlation and regression analyses, relationships of all variables and Ig levels, especially seropositivity of IgG, were investigated.

RESULTS: The mean interval between the symptom onset and the determination of antibodies was 58 days. IgG seropositivity and IgM seropositivity were noted in 82 % and 49 % of HCWs, respectively. Symptom duration was the only statistically significant predictor of IgG seropositivity. With each day of symptom duration, the probability of IgG seropositivity increased from 1.078 to 1.092 times (p < 0.05). If symptoms lasted longer than 17 days, a majority (almost 80 %) of the subjects demonstrated seropositivity in the following months. 
CONCLUSION: The presence of IgG immunity may be assumed from symptom duration. Such easy recognizing of seropositive patients may be a useful tool, e.g. in vaccination strategies (Tab. 3, Fig. 1, Ref. 28).
Keywords: SARS-CoV-2, COVID-19, seropositivity, antibody, immunoglobulin, predictor
Published online: 14-Dec-2021
Year: 2021, Volume: 122, Issue: 12 Page From: 861, Page To: 865
doi:10.4149/BLL_2021_139


download file


© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.